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Background: A beneficial effect of a high n-3 long-chain polyunsaturated fatty acid (LCPUFA) intake has been
observed in heart failure patients, who are frequently insulin resistant. We investigated the potential influence of
impaired glucose metabolism on the relation between dietary intake of n-3 LCPUFAs and risk of acute myocardial
infarction (AMI) in patients with coronary artery disease.
Methods: This prospective cohort study was based on the Western Norway B-Vitamin Intervention Trial and
included 2,378 patients with coronary artery disease with available baseline glycosylated hemoglobin (HbA1c) and
dietary data. Patients were sub-grouped as having no diabetes (HbA1c <5.7%), pre-diabetes (HbA1c ≥5.7%), or
diabetes (previous diabetes, fasting baseline serum glucose ≥7.0, or non-fasting glucose ≥11.1 mmol/L). AMI risk
was evaluated by Cox regression (age and sex adjusted), comparing the upper versus lower tertile of daily dietary
n-3 LCPUFA intake.
Results: The participants (80% males) had a mean age of 62 and follow-up of 4.8 years. A high n-3 LCPUFA intake was
associated with reduced risk of AMI (hazard ratio 0.38, 95%CI 0.18, 0.80) in diabetes patients (median HbA1c = 7.2%),
whereas no association was observed in pre-diabetes patients. In patients without diabetes a high intake tended
to be associated with an increased risk (hazard ratio1.45, 95%CI 0.84, 2.53), which was significant for fatal AMI
(hazard ratio 4.79, 95%CI 1.05, 21.90) and associated with lower HbA1c (mean ± standard deviation 4.55 ±0.68
versus 4.92 ±0.60, P = 0.02). No such differences in HbA1c were observed in those with pre-diabetes or diabetes.
Conclusions: A high intake of n-3 LCPUFAs was associated with a reduced risk of AMI, independent of HbA1c, in
diabetic patients, but with an increased risk of fatal AMI and lower HbA1c among patients without impaired
glucose metabolism. Further studies should investigate whether patients with diabetes may benefit from having a
high intake of n-3 LCPUFAs and whether patients with normal glucose tolerance should be careful with a very
high intake of these fatty acids.
Trial registration: This trial is registered at clinicaltrials.gov as NCT00354081.
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Figure 1 Flow of randomized patients from WENBIT to WENBIT
HbA1c. WENBIT HbA1c designates the present study population with
available dietary and HbA1c data. FFQ, Food Frequency Questionnaire;
WENBIT, Western Norway B-Vitamin Intervention Trial.
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Dietary intakes of fish and omega-3 (n-3) long-chain
polyunsaturated fatty acids (LCPUFAs), mainly eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA),
have been associated with a reduced risk of cardiovascular
disease and mortality [1,2]. A diet rich in these fatty acids
(FAs) is recommended in secondary prevention of coron-
ary heart disease [3]. However, two recent meta-analyses
of randomized controlled trials, investigating n-3 LCPUFA
intake through diet or supplements, failed to demonstrate
an overall preventive effect on cardiovascular events [4,5].
Furthermore, a recent large randomized controlled trial
among patients at high cardiovascular risk showed no
reduction in heart disease or cardiac death after treatment
with 1 g/day of n-3 LCPUFA [6].
Randomized trials with n-3 LCPUFA intervention have
shown reduced mortality [7] and improved left ventricular
systolic function and functional capacity [8,9] among
patients with heart failure, who are frequently insulin
resistant [10]. In general, patients with diabetes mellitus
are at increased risk of cardiovascular disease complications,
including acute myocardial infarction (AMI) and mortality,
as compared to patients without diabetes [11]. There
is, however, conflicting evidence regarding associations
between dietary n-3 LCPUFAs and cardiovascular events
among patients with diabetes [12-17]. A recently published
large randomized controlled trial of 12,536 patients with
dysglycemia (ORIGIN), failed to demonstrate a benefit
of daily n-3 LCPUFA supplementation [18]. Participants
had a baseline dietary n-3 LCPUFA intake of approximately
200 mg/day and median glycosylated hemoglobin (HbA1c)
of 6.4%. The intervention group received 1 g/day of n-3
LCPUFAs, while the placebo group received 1 g/day of
olive oil. Notably, mortality rate in ORIGIN was higher than
could be expected (2.57%) [18] compared to other trials
investigating glucose lowering therapy in patients with
diabetes. The ACCORD trial (baseline median HbA1c 8.1%)
had a mortality rate of 1.41% in the intensive treatment
group and demonstrated that aggressive glucose lowering
in patients with diabetes, targeting HbA1c <6.0%, may
be associated with increased mortality [19]. Based on
this, the overall intensive glucose lowering in ORIGIN
may have influenced the negative results regarding n-3
LCPUFA supplements.
Our previous investigation on the current population
of Norwegian patients with established coronary artery
disease (CAD) showed no overall reduction in risk of
coronary events with increasing intakes of n-3 LCPUFAs
[20]. No sub-group analyses were, however, conducted.
Based on the reported beneficial effects in patients with
heart failure [7-9], the current investigation evaluated
the association of n-3 LCPUFA intake with risk of AMI in
patients with no diabetes, pre-diabetes, or established
diabetes, respectively, in the patient cohort previouslystudied. We hypothesized that participants with diabetes
mellitus would benefit from a high intake of n-3 LCPUFAs.
Methods
Study population
The current investigation was a prospective cohort study
based on participants from the Western Norway B-Vitamin
Intervention Trial (WENBIT) [21]. In short, this was a clin-
ical trial conducted between 1999 and 2006 at Haukeland
University Hospital and Stavanger University Hospital
in Western Norway, including 3,090 patients undergo-
ing coronary angiography for suspected CAD, and who
were randomized to treatment with B vitamins. Overall,
there was no short- or long-term benefits on cardiovascular
outcomes or all-cause mortality associated with the
study treatment [21].
Figure 1 gives an overview of patient selection for
the final inclusion in the present analysis based on 2,484
patients who completed a semi-quantitative food-frequency
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2004. Nineteen questionnaires were excluded because they
contained more than one blank page. Extreme outliers of
dietary intake were excluded based on the assumption that
these did not represent their usual daily intakes. These
outliers were identified by participants having very low
(<3,000 kJ for women and <3,300 kJ for men) or very high
(>15,000 kJ for women and >17,500 kJ for men) estimated
daily energy intakes (n = 53), leaving 2,412 patients with
valid dietary data. Further, 34 individuals were excluded
because of missing HbA1c data, leaving 2,378 patients for
the final analyses. Serum FA composition was determined
in a sub-set of 723 patients.
All participants gave written informed consent. The
study protocol was in accordance with the principles of
the Declaration of Helsinki, and it was approved by the
Regional Committee for Medical Research Ethics, the
Norwegian Medicines Agency, and the Data Inspectorate.
WENBIT is registered at clinicaltrials.gov as NCT00354081.
Dietary assessment
An FFQ developed at the Department of Nutrition,
University of Oslo, validated against plasma phospholipid
n-3 LCPUFA concentrations [22], was given to patients
at enrolment and returned by mail to the study center
or collected at the first follow-up appointment one month
later. A more detailed description of the structure and
organization of the 169 food item FFQ and inclusion/
exclusion criteria for this sub-study have been given
previously [20]. Briefly, the usual daily intake of n-3
LCPUFAs during the last year was estimated based on
FFQ reported food items and supplements containing
EPA, docosapentaenoic acid (DPA, 22:5n-3), and DHA.
Calculations were made by using a database and a soft-
ware system developed at the Department of Nutrition,
University of Oslo (Kostberegningssystem, version 3.2;
University of Oslo, Norway) [23].
Assessment of other covariates
Demographic, clinical, and routine laboratory data were
obtained by study personnel at the respective two study
centers as previously described [21]. Serum samples were
collected before angiography and stored at −80°C until
analysis, while standard blood laboratory parameters
were analyzed from fresh samples according to routine
protocols at their central hospital laboratories. Reagent kits
of type Tina-quant® on apolipoprotein A-I (Apo A-I, ver.2),
apolipoprotein B (Apo B, ver.2), and C-reactive protein
(latex, high sensitive assay) were obtained from Roche
Diagnostics (Mannheim, Germany), and serum measure-
ments were done on the Hitachi 917 system (Roche
Diagnostics). HbA1c was determined by matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
[24] and plasma cotinine by liquid chromatography/tandemmass spectrometry at BEVITAL AS (http://www.bevital.no,
Bergen, Norway). Serum FA methyl esters were obtained
and analyzed by gas–liquid chromatography as previ-
ously described [25]. Smokers included self-reported
current smokers, those reported having quit within the last
four weeks, and patients with plasma cotinine ≥85 nmol/L.
Left ventricular ejection fraction was determined by
ventriculography or echocardiography, and values <50%
were considered equaling impaired systolic function. Esti-
mated glomerular filtration rate was calculated applying
the equation by the Chronic Kidney Disease Epidemiology
Collaboration [26]. Extent of CAD was graded as clinically
non-significant stenosis (luminal narrowing <50%), or
as having single-, double-, or triple vessel disease.
Endpoints and follow-up
The endpoints in this study were fatal and non-fatal AMI,
classified according to the diagnostic criteria of the re-
vised definition of myocardial infarction from 2000 [27].
Procedure-related non-fatal AMI occurring ≤24 hours after
coronary angiography, percutaneous coronary intervention
(PCI), or coronary artery bypass graft surgery (CABG) were
excluded. Information on AMIs was collected from the
Western Norway Cardiovascular Registry and from the
Norwegian Cause of Death Registry. Endpoints were
recorded during in-trial and post-trial follow-up until
31 December 2006, and all events were adjudicated by
members of the WENBIT endpoints committee.
Statistical analyses
Categorization of the participants was based on established
diagnostic criteria for no-, pre-, and overt diabetes mellitus
[28]. Participants were thus classified as non-diabetic
(no prior history of diabetes and HbA1c <5.7%), pre-
diabetic (no prior history of diabetes and HbA1c ≥5.7%),
and diabetic (previously diagnosed diabetes or fasting
baseline serum glucose ≥7.0 or a non-fasting glu-
cose ≥11.1 mmol/L). Means (± standard deviation (SD))
or medians (25th, 75th percentile) and proportions of
various clinical and biochemical parameters were cal-
culated for selected baseline characteristics and dietary
variables within each category. Simple comparisons of
continuous variables within or between sub-groups were
made by the t-test. Spearman’s rank correlation was
used to assess associations between various continuous
parameters. The Kolmogorov-Smirnov test was used to
examine the continuous FA variables for normal distri-
bution. Variables that were not normally distributed
were log-transformed. Estimated marginal means (95%
confidence interval (CI)) of FA profile were calculated
for each sub-group by one-way analysis of covariance,
with adjustments made for age, sex, and statin dose.
Post-hoc comparisons were made by using the Tukey hon-
estly significant difference for specifying between-group
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of covariance.
Participants within each group were ranked into tertiles
according to combined daily n-3 LCPUFA (EPA, DPA, and
DHA) intake as percentage of total energy (%TE) intake.
Survival curves were created for follow-up until the 95th
percentile of follow-up time (corresponding to 6.8 years)
using the Kaplan-Meier method. Hazard ratios (HRs) and
95% CI were estimated by Cox proportional hazards
modeling. Tests for trend were performed using estimated
daily n-3 LCPUFA tertiles as a continuous variable in
otherwise identical models. The basic model included age
and sex. Additional covariates in the multivariate model
were selected on the basis of clinical relevance and included
the following: fasting (dichotomous), current smoking
(dichotomous) [29], extent of CAD (non-significant; single-,
double-, or triple-vessel disease), left ventricular ejection
fraction (continuous), serum triglycerides (continuous),
baseline acute coronary syndrome (dichotomous), baseline
PCI (dichotomous), baseline CABG (dichotomous), and
randomization to treatment with folic acid or vitamin B6
study medication (dichotomous). Interactions between
intake of n-3 LCPUFAs and diabetes were tested by adding
interaction product terms in the model. Additional adjust-
ments for the following covariates did not appreciably
alter the results and were not included in the final model:
body mass index (continuous); current use of statins,
β-blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, metformin, sulfonamides,
and insulin (dichotomous for all); history of hypertension
(dichotomous); and apolipoprotein A-I and B, HbA1c, or
C-reactive protein (continuous for all).
Statistics were performed using IBM SPSS Statistics for
Windows, version 19 (SPSS, Chicago, IL, USA) and R
version 2.15.2 (R Development Core Team, Vienna, Austria).
Two-sided P-values <0.05 were considered statistically
significant.
Results
Baseline characteristics and dietary intakes
At baseline, the mean age of the participants was 61.6 years
and 80.4% were men. Further, 84.6% had stable angina
pectoris. A total of 46.6% were treated for hypertension and
31.1% were current smokers. A previous myocardial infarc-
tion was reported in 41.3%, PCI in 21.5%, and CABG in
14.0% of the patients. On baseline coronary angiography,
11.2% were diagnosed with non-significant CAD, and 32.0%
had three-vessel disease. At discharge from hospital, 90.1%
of the participants were treated with aspirin, 22.7% with
calcium channel blockers, and 9.3% with loop diuretics.
A total of 1,577 patients (66.3%) underwent myocardial
revascularization with either PCI or CABG. There were
1,012 patients (42.6%) classified as non-diabetic, 1,049
(44.1%) classified as pre-diabetic, and 317 (13.3%) classifiedas diabetic, of whom 16 (0.7%) had type 1 and 301 (12.7%)
type 2 diabetes.
Characteristics of participants in the sub-groups are
presented in Table 1. Patients with diabetes (median HbA1c
7.2%) were older (P = 0.001), had a higher body mass index
(P <0.001), and more frequently had hypertension (P <0.001).
As expected, they had overall higher triglycerides (P <0.001)
and lower apolipoprotein A-I (P <0.001) compared to non-
and pre-diabetic participants. Patients with diabetes also had
a higher intake of total fat (P = 0.02) and monounsatu-
rated fat (P = 0.002). There were no differences between
the groups regarding intakes of saturated and trans fat.
Dietary intake of n-3 LCPUFAs and fish
Mean (±SD) daily dietary intakes of n-3 LCPUFAs among
all 2,378 participants were 0.43 ±0.24, 1.08 ±0.37, and
2.38 ±1.15 g/day for tertiles 1 to 3 of n-3 LCPUFA, respect-
ively. Adjusted for energy intake, this corresponded to
0.18 ±0.08, 0.45 ±0.09, and 1.03 ±0.40 %TE, respectively.
Mean (±SD) intakes of n-3 LCPUFAs (%TE) were 0.56 ±0.44
for non-diabetic, 0.54 ±0.40 for pre-diabetic, and 0.60 ±0.46
for diabetic patients. Intakes were higher among diabetic pa-
tients compared to pre-diabetic patients (P = 0.04). Tertiles
of mean (±SD) daily intakes according to the sub-groups
were 0.17 ±0.08, 0.44 ±0.09, and 1.05 ±0.42 %TE for non-
diabetic patients; 0.18 ±0.08, 0.44 ±0.08, and 0.98 ±0.38 %TE
for pre-diabetic patients; and 0.19 ±0.08, 0.48 ±0.11, and
1.12 ±0.42 %TE for patients with diabetes. Total daily
fish intake (mean ±SD) in tertiles 1 to 3 was 47.7 ±19.0,
98.0 ±13.7, and 180.7 ±62.1 g/day, respectively.
Serum fatty acid profile
FA profile in serum from a sub-cohort of 723 patients was
used to determine whether estimated dietary intake of FAs
was reflected in serum. We observed a strong association
between reported intake and serum total n-3 LCPUFAs
(Spearman’s rho = 0.515, P <0.001). Table 2 shows main
serum FA profile in percentage by weight (wt%) of total FAs
in sub-groups of patients with no diabetes (n=380), pre-
diabetes (n = 259), and diabetes (n = 84). When adjusted
for age, sex, and statin dose, serum total FAs (mg/L) were
borderline significantly higher in the diabetic group as
compared to those with pre-diabetes (Tukey honestly
significant difference, P = 0.05). Furthermore, serum
saturated FAs were higher (wt%) while n-6 PUFAs were
lower in patients with diabetes compared to those with
no diabetes and pre-diabetes (Tukey honestly significant
difference, P <0.05 for all between-group comparisons).
There was no difference in total or individual n-3 LCPUFAs
between the three sub-groups.
Follow-up and events
Mean (±SD) length of follow-up was 4.8 ±1.4 years. A total
of 208 participants (8.7%) experienced a fatal or non-fatal
Table 1 Baseline characteristics of participants (n = 2,378)
Non-diabetes
HbA1c <5.7%
Pre-diabetes
HbA1c ≥5.7%
Diabetesa Pb
n = 1,012 n = 1,049 n = 317
Age (y) 61.0 ±9.9c 61.8 ±9.5 63.1 ±9.5 0.001
Male sex (n (%)) 800 (79.1) 855 (81.5) 256 (80.8) 0.28
Body mass index (kg/m2) 26.5 ±3.4 26.7 ±3.6 28.4 ±4.3 <0.001
Coronary history (n (%))
Myocardial infarction 410 (40.5) 432 (41.2) 139 (43.8) 0.34
Percutaneous coronary intervention 209 (20.7) 229 (21.8) 74 (23.3) 0.29
Coronary artery bypass graft surgery 135 (13.3) 150 (14.3) 47 (14.8) 0.44
Coronary risk factors (n (%))
Hypertensiond 430 (42.5) 461 (43.9) 217 (68.5) <0.001
Current smokere 313 (30.9) 339 (32.3) 88 (27.8) 0.57
Serum lipids
Triglycerides (mmol/L) 1.73 ±1.28 1.76 ±1.00 2.17 ±1.27 <0.001
Apolipoprotein A-I (g/L) 1.28 ±0.25 1.24 ±0.25 1.22 ±0.26 <0.001
Apolipoprotein B (g/L) 0.90 ±0.25 0.86 ±0.23 0.88 ±0.22 0.004
Glucose status
Glucose (mmol/L) 5.6 ±1.1 5.8 ±1.1 9.8 ±3.4 <0.001
HbA1c (%) 4.9 ±0.6 6.5 ±0.8 7.5 ±1.8 <0.001
Inflammation markers and renal function
C-reactive protein (mg/L)f 1.76 (0.85, 3.68) 1.85 (0.89, 4.23) 2.07 (1.00, 4.40) 0.45
Estimated glomerular filtration rate (mL/min) 90.0 ±15.3 90.7 ±14.4 88.8 ±17.5 0.61
LVEF and severity of coronary artery disease at baseline angiography (n (%))
LVEF <50% 89 (8.8) 118 (11.2) 44 (13.9) 0.006
Three-vessel disease 316 (31.2) 330 (31.5) 115 (36.3) 0.19
Medication at discharge from hospital (n (%))
Statins 889 (87.8) 948 (90.4) 280 (88.3) 0.35
β-blockers 800 (79.1) 817 (77.9) 236 (74.4) 0.11
ACE inhibitors/ARBs 263 (26.0) 330 (31.5) 159 (50.2) <0.001
Metformin 0 (0) 0 (0) 98 (30.9) 0.98
Sulfonamides 0 (0) 0 (0) 79 (24.9) 0.98
Insulin 0 (0) 0 (0) 77 (24.3) 0.98
Other anti-diabetic drugs 0 (0) 0 (0) 4 (1.3) 0.98
Estimated daily dietary intakes
Energy (kJ) 8,790 ±2,560 8,900 ±2,740 8,300 ±2,680 0.06
Total fat (%TE) 31.2 ±5.4 31.4 ±5.4 32.2 ±6.2 0.02
Saturated and trans fat (%TE) 11.6 ±2.6 11.6 ±2.6 11.7 ±2.8 0.35
Monounsaturated fat (%TE) 10.1 ±1.9 10.1 ±1.9 10.5 ±2.2 0.002
Polyunsaturated fat (%TE) 7.0 ±1.9 7.0 ±2.0 7.3 ±2.3 0.07
n-6 PUFAs (g)g 13.3 ±6.3 13.6 ±6.7 13.1 ±6.6 0.96
n-3 PUFAs (g)h 3.23 ±1.54 3.25 ±1.61 3.24 ±1.67 0.89
n-3 LCPUFAs (g)i 1.30 ±1.11 1.28 ±1.05 1.32 ±1.06 0.96
n-3 LCPUFAs (%TE)i 0.56 ±0.44 0.54 ±0.40 0.60 ±0.46 0.45
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Table 1 Baseline characteristics of participants (n = 2,378) (Continued)
Use of dietary supplements (n (%))
Fish oil 167 (16.5) 171 (16.3) 49 (15.5) 0.69
Cod liver oil 272 (26.9) 294 (28.0) 80 (25.2) 0.83
Folic acid 500 (49.4) 523 (49.9) 161 (50.8) 0.68
Vitamin B6 508 (50.2) 545 (52.0) 145 (45.7) 0.44
aDiabetes was defined as clinically diagnosed, or as having a fasting glucose ≥7.0 or a non-fasting glucose ≥11.1 mmol/L. bCalculated by using linear regression
for continuous variables and logistic regression for binary variables. cMean ±SD (all such values). dReceiving medical treatment for hypertension. eCurrent smoker
(self-reported, ex-smoker <1 month, or cotinine ≥85 nmol/L). fValues are medians (25th, 75th percentiles). gComposed of linoleic and arachidonic acids.
hComposed of α-linolenic acid, EPA, DPA, and DHA. iComposed of EPA, DPA, and DHA. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker;
DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HbA1c, glycosylated hemoglobin; LVEF, left ventricular ejection fraction; n-3
LCPUFAs, n-3 long-chain polyunsaturated fatty acids; PUFAs, polyunsaturated fatty acids; %TE, percentage of total energy.
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8.4% for pre-diabetic, and 13.6% for diabetic patients.
Intake of n-3 LCPUFAs and risk of acute myocardial infarction
Figure 2 illustrates the crude event-free survival time from
AMI among patients with or without diabetes in tertiles
of n-3 LCPUFA intake. The age and sex- and multivariate-
adjusted HRs for AMI according to tertiles of n-3 LCPUFA
consumption (%TE) in sub-groups, as estimated by Cox
proportional hazards modeling, are presented in Table 3.
Compared to the lower tertile, the multivariate adjusted risk
of experiencing an AMI was non-significantly increased by
55% among patients without diabetes, having intakes corre-
sponding to the upper tertile (P = 0.13). There was no as-
sociation between n-3 LCPUFA consumption and risk of
AMI in patients with pre-diabetes, and restricting the ana-
lysis to patients with HbA1c ≥6.5% (n = 423) provided simi-
lar results (data not shown). Among patients with diabetes,
there was a 62% risk reduction of experiencing an AMI in
the upper compared to the lower tertile of n-3 LCPUFA
intakes in multivariate analysis (P = 0.02), and there was
also a dose–response effect (P for trend = 0.01). AddingTable 2 Serum fatty acid profile in percentage by weight (wt%
Non-diabetes HbA1c <5.7%
n = 380
Total FAs (mg/L) 3,790 (3,680 to 3,900)c
Saturated FAs 33.2 (32.9 to 33.4)
Monounsaturated FAs 22.9 (22.5 to 23.2)
n-6 PUFAs 35.0 (34.4 to 35.5)
n-3 PUFAs 7.2 (7.0 to 7.5)
α-Linolenic acid 0.71 (0.69 to 0.73)
Eicosapentaenoic acid 1.80 (1.68 to 1.92)
Docosapentaenoic acid (n-3) 0.62 (0.60 to 0.63)
Docosahexaenoic acid 3.69 (3.56 to 3.82)
n-3 PUFA / n-6 PUFA ratio 0.21 (0.20 to 0.22)
aDiabetes was defined as clinically diagnosed, or as having a fasting glucose ≥7.0 o
covariance, after log transformation, adjusted for age, sex, and statin dose. cEstimat
HbA1c, glycosylated hemoglobin; PUFAs, polyunsaturated fatty acids.all patients with HbA1c ≥6.5% to the diabetes group clearly
attenuated the associations, providing a multivariate
adjusted HR (95% CI) of 0.71 (0.40, 1.26) in the upper versus
lower tertile of n-3 LCPUFA intakes and no dose–response
relationship. Estimates based on mg/day amounts of n-3
LCPUFAs were very similar and did not introduce any
material changes to the percentage of total energy findings
(data not shown). There were no clear associations between
total fish intake and AMI risk (Table 3).
Conventional criteria on diagnosing diabetes by blood
glucose rely on two separate measurements [28]. Since
59 patients were included in the diabetes group based on
baseline glucose from one single measurement, we did a
separate sensitivity analysis among the 258 patients who
were diagnosed with diabetes prior to baseline examination,
and this did not change the results (data not shown).
Because patients with diabetes tended to have an increased
n-3 LCPUFA intake compared to the others, we repeated
the analysis on the diabetes sub-group using tertiles based
on the total population. This analysis provided similar
results (data not shown). There was an interaction between
diabetes and n-3 LCPUFA in a multivariate adjusted) measured in 723 participants
Pre-diabetes HbA1c ≥5.7% Diabetesa Pb
n = 259 n = 84
3,680 (3,560 to 3,810) 4,050 (3,820 to 4,300) 0.02
33.2 (32.9 to 33.5) 34.0 (33.5 to 34.5) 0.01
23.2 (22.7 to 23.6) 24.0 (23.2 to 24.8) 0.03
34.5 (33.9 to 35.2) 32.8 (31.8 to 33.9) 0.002
7.4 (7.1 to 7.8) 7.2 (6.6 to 7.8) 0.61
0.73 (0.70 to 0.75) 0.72 (0.68 to 0.77) 0.38
1.91 (1.76 to 2.07) 1.78 (1.54 to 2.05) 0.49
0.63 (0.61 to 0.65) 0.62 (0.58 to 0.65) 0.55
3.73 (3.58 to 3.90) 3.63 (3.37 to 3.91) 0.79
0.22 (0.20 to 0.23) 0.22 (0.20 to 0.24) 0.41
r a non-fasting glucose ≥11.1 mmol/L. bCalculated by using one-way analysis of
ed marginal means; 95% CI in parentheses (all such values). FAs, fatty acids;
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Figure 2 Kaplan-Meier plot illustrating survival in patients with or without diabetes mellitus. Survival plot showing time to an acute
myocardial infarction in each tertile of n-3 LCPUFA intakes (designated as Tertile 1, 2, and 3) in patients without diabetes (HbA1c <5.7%)
(left panel) and with diabetes (right panel). Estimates were based on follow-up until the 95th percentile (6.8 years).
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study treatment with B vitamins according to the WENBIT
study design did not materially affect any of the results.
We also performed stratified analyses according to fatal-
and non-fatal AMI as outcomes (Table 4). Among patients
without diabetes, HR (95% CI) for fatal AMI was 4.79
(1.05, 21.90) in the upper versus lower tertile of n-3
LCPUFA intake (P for trend = 0.02). In patients with
diabetes, HR (95% CI) for fatal AMI was 0.22 (0.06, 0.81) in
tertile 3 compared to tertile 1 (P for trend = 0.02). For
non-fatal AMI, there was no change in risk among patientsTable 3 Risk of total acute myocardial infarction by dietary n
and fish (grams) tertiles
Non-diabetes (HbA1c <5.7%, n = 1,012) Pre-diab
Age/sex adjusted Multivariateb Age/sex
Number of events 77
n-3 LCPUFA
Tertile 1c 1.00 1.00
Tertile 2d 1.12 (0.63, 2.02) 0.93 (0.49, 1.77) 1.16 (0.
Tertile 3e 1.45 (0.84, 2.53) 1.55 (0.87, 2.76) 1.16 (0
P for trend 0.17 0.11
Total fish
Tertile 1f 1.00 1.00
Tertile 2g 1.68 (0.97, 2.89) 1.51 (0.84, 2.72) 0.85 (0
Tertile 3h 1.02 (0.55, 1.88) 1.19 (0.63, 2.27) 1.05 (0
P for trend 0.96 0.60
Hazard ratios and 95% confidence intervals were calculated using Cox proportional
glucose ≥7.0 or a non-fasting glucose ≥11.1 mmol/L. bMultivariate model adjusted
of coronary artery disease (non-significant; single, double, or triple vessel), left vent
acute coronary syndrome (yes or no), baseline percutaneous coronary intervention
treatment with folic acid or vitamin B6 supplements (yes or no). cn = 337 in non-di
non-diabetic, n = 350 in pre-diabetic, and n = 106 in diabetic patients. en = 337 in
in non-diabetic, n = 354 in pre-diabetic, and n = 105 in diabetic patients. gn = 335
hn = 338 in non-diabetic, n = 353 in pre-diabetic, and n = 104 in diabetic patients.
fatty acids (eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acwithout diabetes, but a non-significant trend towards a
reduced risk with increasing intakes among patients
with diabetes. Due to the low number of events in each
sub-group, the multivariate model did not converge for
separate fatal- and non-fatal AMIs. Thus, only age-
and sex adjusted HRs were presented for these separate
endpoints (Table 4).
Post hoc comparisons within the non-diabetic group
revealed that HbA1c was lower in tertiles 2 (P = 0.008) and
3 (P = 0.01), compared to tertile 1 of n-3 LCPUFA intakes
(mean ±SD 4.87 ±0.62 and 4.87 ±0.65 versus 4.99 ±0.54).-3 LCPUFA (as a percentage of total energy intake)
etes (HbA1c ≥5.7%, n = 1,049) Diabetes (n = 317)a
adjusted Multivariateb Age/sex adjusted Multivariateb
88 43
1.00 1.00 1.00 1.00
69 to 1.95) 1.20 (0.70, 2.06) 0.43 (0.21, 0.88) 0.48 (0.22, 1.06)
.69, 1.95) 1.33 (0.77, 2.28) 0.38 (0.18, 0.80) 0.38 (0.17, 0.83)
0.59 0.30 0.007 0.01
1.00 1.00 1.00 1.00
.50, 1.44) 0.88 (0.51, 1.52) 0.87 (0.44, 1.71) 0.94 (0.45, 1.98)
.63, 1.74) 1.10 (0.65, 1.85) 0.56 (0.26, 1.24) 0.66 (0.29, 1.53)
0.84 0.70 0.16 0.34
hazards. aDiabetes was defined as clinically diagnosed, or as having a fasting
for age (continuous), sex, fasting (yes or no), current smoker (yes or no), extent
ricular ejection fraction (continuous), serum triglycerides (continuous), baseline
(yes or no), baseline coronary artery bypass graft surgery (yes or no), and
abetic, n = 349 in pre-diabetic, and n = 105 in diabetic patients. dn = 338 in
non-diabetic, n = 350 in pre-diabetic, and n = 106 in diabetic patients. fn = 339
in non-diabetic, n = 342 in pre-diabetic, and n = 108 in diabetic patients.
HbA1c, glycosylated hemoglobin; n-3 LCPUFA, n-3 long-chain polyunsaturated
id).
Table 4 Risk of acute myocardial infarction (separate fatal and non-fatal) by dietary n-3 LCPUFA tertiles
(as a percentage of total energy intake)
Non-diabetes
(HbA1c <5.7%, n = 1,012)
Pre-diabetes
(HbA1c ≥5.7%, n = 1,049)
Diabetes (n = 317)a
Fatal AMI (events) 16 20 18
Tertile 1b 1.00 1.00 1.00
Tertile 2c 1.98 (0.36, 10.82) 1.85 (0.56, 6.15) 0.39 (0.13, 1.15)
Tertile 3d 4.79 (1.05, 21.90) 1.84 (0.56, 6.13) 0.22 (0.06, 0.81)
P for trend 0.02 0.34 0.02
Non-fatal AMI (events) 61 68 25
Tertile 1b 1.00 1.00 1.00
Tertile 2c 1.03 (0.55 to 1.93) 1.04 (0.58 to 1.87) 0.45 (0.17 to 1.20)
Tertile 3d 1.10 (0.60 to 2.04) 1.04 (0.58 to 1.86) 0.52 (0.20 to 1.32)
P for trend 0.75 0.91 0.14
Hazard ratios and 95% confidence intervals were calculated using Cox proportional hazards. The model was adjusted for age (continuous) and sex. aDiabetes was
defined as clinically diagnosed, or as having a fasting glucose ≥7.0 or a non-fasting glucose ≥11.1 mmol/L. bn = 337 in non-diabetic, n = 349 in pre-diabetic, and
n = 105 in diabetic patients. cn = 338 in non-diabetic, n = 350 in pre-diabetic, and n = 106 in diabetic patients. dn = 337 in non-diabetic, n = 350 in pre-diabetic,
and n = 106 in diabetic patients. HbA1c, glycosylated hemoglobin; n-3 LCPUFA, n-3 long-chain polyunsaturated fatty acids (eicosapentaenoic acid,
docosapentaenoic acid, and docosahexaenoic acid).
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an AMI did also have a lower HbA1c than those who
did not have an AMI event (mean ±SD 4.77 ±0.63 versus
4.92 ±0.60, P = 0.04). This association was more pronounced
among those who had a fatal AMI event (mean ±SD
4.55 ±0.68 versus 4.92 ±0.60, P = 0.02). No such differences
were observed in those with pre-diabetes or diabetes.
Discussion
The main finding in this observational cohort study among
patients with established CAD was that a high intake of n-3
LCPUFAs was associated with a reduced risk of total AMI,
independent of HbA1c, in patients with diabetes, but with
an increased risk of fatal AMI and with lower HbA1c in
those without impaired glucose metabolism.
One of the strengths of this study was its large, well-
characterized population with long-term follow-up and
extensive dietary information. Data are scarce on the
association between dietary intake of n-3 LCPUFA and AMI
in statin-treated patients with CAD, since most previous
studies have based their results on circulating n-3 LCPUFAs
and many investigations have been performed in groups that
did not receive statins. This study helps address this gap in
data. All endpoints in the current study were validated by a
committee blinded to the dietary information.
This study also had certain limitations. Our study had
limited power to detect significant effects due to the
smaller sample size of sub-groups and the low event rate
primarily in the non-diabetes group. Furthermore, FFQs
were not checked for errors when received at the study
center, and participants with extreme values or partially
missing reported intakes were excluded ahead of this
sub-study. The remaining data were considered valid, as
dietary intakes were comparable to previous surveys inthe region using the same questionnaire [30]. Information
on dietary habits was collected at baseline, reflecting the
average intake during the past year, whereas no information
on dietary habits was collected during follow-up. Thus,
there is a possibility of a regression dilution bias, which
probably would have strengthened rather than attenuated
the results. Despite careful adjustments for available im-
portant covariates, prospective cohort studies are typic-
ally limited by confounding from both unmeasured and
inappropriately measured factors.
Similar to our previous investigation [20], a study among
post-AMI patients did not report any overall relations
between n-3 LCPUFAs and cardiovascular events [31].
However, in accordance with our current results, a post hoc
analysis among participants with diabetes revealed a strong
decline in ventricular arrhythmia-related events and fatal
AMI with increased n-3 LCPUFA intake [32]. Other studies
have also indicated that a high intake may reduce the risk
of non-fatal AMI [33-36]. A recent study concluded that
n-3 PUFA supplementation might have the ability to reduce
cardiovascular events in patients not treated with statins
[37], whereas no additional benefits were observed among
statin users [37]. The majority of patients in the present
study were treated with statins. Thus, our data indicate
that n-3 LCPUFA intake is associated with AMI risk,
and particularly fatal events, also in statin users.
The main question is whether our findings are observed
by chance or report real effects of n-3 LCPUFA intake. No
effects of n-3 LCPUFA supplementation were revealed in
the large ORIGIN study among dysglycemic patients [18].
These participants had a low baseline dietary intake of n-3
LCPUFAs, and even after receiving study treatment, daily
n-3 LCPUFA intake was only about half compared to those
having the highest intakes in our population. Additionally,
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eral other randomized trials [38]. This oil contains various
FAs, and its use as placebo may thus have influenced the
results. Furthermore, participants in ORIGIN had a median
HbA1c of 6.4%, whereas patients with diabetes in the
current study had a median HbA1c of 7.2%. Patients with
HbA1c ≥9.0% were excluded from ORIGIN, whereas those
with fasting plasma glucose ≥6.1 mmol/L were included. In
a separate analysis in our cohort, we included all patients
with HbA1c ≥6.5% together with the patients diagnosed
with diabetes, which attenuated the results. Based on these
considerations, the diabetes group in our study differs
clearly from the dysglycemic patients in ORIGIN, having a
similar average HbA1c as in our sub-group of patients with
pre-diabetes where no association with n-3 LCPUFA
was observed. Notably, the ACCORD study among pa-
tients with diabetes having baseline median HbA1c 8.1%
demonstrated adverse effects with an increased mortality
after aggressive glucose lowering treatment [19]. Thus,
the overall intensive glucose lowering in ORIGIN may
also have influenced outcome following n-3 LCPUFA
supplementation.
Dietary n-3 LCPUFAs are predominantly present in fish
and seafood, in which oily fish is a major source. Existing
international guidelines recommend an n-3 LCPUFA intake
of at least 250 mg/day or two servings of oily fish per week
[39]. Despite the observed associations between dietary n-3
LCPUFAs and AMI risk, no clear associations could be
seen for fish intake. This might be explained by a frequent
use of cod liver and/or fish oils among those having the
highest intakes of n-3 LCPUFAs, with 70% using such sup-
plements in the upper tertile (data not shown). Even though
n-3 LCPUFA supplements like cod liver and fish oils were
frequently used, fish consumption was also relatively high
in this cohort. Thus, we cannot exclude that other fish
ingredients may have influenced the results.
Another prominent finding in the present study was
the strong association between a high intake of n-3
LCPUFAs and fatal AMI in patients without diabetes with
HbA1c <5.7%. Dietary intake of high-dose n-3 LCPUFA
has also in some previous studies been associated with
adverse effects. A study in South Wales on male patients
with angina pectoris revealed an increased risk of cardiac
death among participants advised to eat oily fish or fish oil
capsules [40]. Furthermore, a canine model showed a pro-
arrhythmic effect after high-dose n-3 PUFA supplementa-
tion in dogs not originally vulnerable to ischemia [41].
Through a post hoc comparison within the non-diabetic
group, we demonstrated an overall lower HbA1c in those
having the highest intake of n-3 LCPUFAs and in those
who experienced a fatal AMI compared to the other in-
dividuals within the non-diabetic group. A previous
prospective cohort study demonstrated an increased risk
of all-cause death among individuals with HbA1c <5.0%(no diabetes) [42]. A link has been demonstrated between
hypoglycemia, endothelial dysfunction, and increased oxi-
dative stress [43], which could produce a certain metabolic
profile. Accordingly, high-dose fish oil supplementation
has also been associated with increased oxidative damage
in rats [44]. In view of our own observations, it is curious
to note that when fasted, dienoyl-CoA reductase (Decr) null
mutant mice develop hypoglycemia and accumulate PUFAs
in their tissues, indicating an impaired mitochondrial
β-oxidation [45]. This may further suggest a reverse rela-
tionship between PUFAs and blood glucose in fasted
individuals. Our findings could imply that high-dose n-3
LCPUFA consumption among patients without diabetes
or impairment of glucose tolerance might reduce overall
blood glucose and increase the risk of fatal AMI. Notably,
no association was seen between HbA1c and the n-3
LCPUFA effects among patients with diabetes.
Altogether, additional studies are needed to validate our
findings and further elucidate mechanisms behind the
observed associations. Based on future research, it should
be concluded whether it is time for a reassessment of
the current dietary advices on n-3 LCPUFAs in secondary
prevention of CAD [3].
Conclusions
In this cohort of patients with established CAD, a high
intake of n-3 LCPUFAs was associated with reduced risk
of AMI, independent of HbA1c, in patients with diabetes.
In patients without diabetes, a high intake was associated
with increased risk of fatal AMI and lower HbA1c. These
findings should motivate further studies on potential
beneficial or adverse effects of a high n-3 LCPUFA intake
in sub-groups of patients with CAD.
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